• IMMUNE NETWORK
• /
• 제15권2호
• /
• pp.51-57
• /
• 2015

Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.

• IMMUNE NETWORK
• /
• 제4권3호
• /
• pp.131-142
• /
• 2004

In recent years, adjuvants have received much attention because of the development of purified subunit and synthetic vaccines which are poor immunogens and require adjuvants to evoke the immune response. Therefore, immunologic adjuvants have been developed and testing for most of this century. During the last years much progress has been made on development, isolation and chemical synthesis of alternative adjuvants such as derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS-21, MF-59 and immunostimulating complexes (ISCOMS). Biodegradable polymer microspheres are being evaluated for targeting antigens on mucosal surfaces and for controlled release of vaccines with an aim to reduce the number of doses required for primary immunization. The most common adjuvants for human use today are aluminum hydroxide and aluminum phosphate. Calcium phosphate and oil emulsions have been also used in human vaccination. The biggest issue with the use of adjuvants for human vaccines is the toxicity and adverse side effects of most of the adjuvant formulations. Other problems with the development of adjuvants include restricted adjuvanticity of certain formulations to a few antigens, use of aluminum adjuvants as reference adjuvant preparations under suboptimal conditions, non-availability of reliable animal models, use of non-standard assays and biological differences between animal models and humans leading to the failure of promising formulations to show adjuvanticity in clinical trials. The availability of hundreds of different adjuvants has prompted a need for identifying rational standards for selection of adjuvant formulations based on safety and sound immunological principles for human vaccines. The aim of the present review is to put the recent findings into a broader perspective to facilitate the application of these adjuvants in general and experimental vaccinology.

• Journal of Veterinary Science
• /
• 제21권5호
• /
• pp.74.1-74.13
• /
• 2020

Background: The quality of a vaccine depends strongly on the effects of the adjuvants applied simultaneously with the antigen in the vaccine. The adjuvants enhance the protective effect of the vaccine against a viral challenge. Conversely, oil-type adjuvants leave oil residue inside the bodies of the injected animals that can produce a local reaction in the muscle. The long-term immunogenicity of mice after vaccination was examined. ISA206 or ISA15 oil adjuvants maintained the best immunity, protective capability, and safety among the oil adjuvants in the experimental group. Objectives: This study screened the adjuvant composites aimed at enhancing foot-and-mouth disease (FMD) immunity. The C-type lectin or toll-like receptor (TLR) agonist showed the most improved protection rate. Methods: Experimental vaccines were fabricated by mixing various known oil adjuvants and composites that can act as immunogenic adjuvants (gel, saponin, and other components) and examined the enhancement effect on the vaccine. Results: The water in oil (W/O) and water in oil in water (W/O/W) adjuvants showed better immune effects than the oil in water (O/W) adjuvants, which have a small volume of oil component. The W/O type left the largest amount of oil residue, followed by W/O/W and O/W types. In the mouse model, intramuscular inoculation showed a better protection rate than subcutaneous inoculation. Moreover, the protective effect was particularly weak in the case of inoculation in fatty tissue. The initial immune reaction and persistence of long-term immunity were also confirmed in an immune reaction on pigs. Conclusions: The new experimental vaccine with immunostimulants produces improved immune responses and safety in pigs than general oil-adjuvanted vaccines.

• Asian-Australasian Journal of Animal Sciences
• /
• 제29권7호
• /
• pp.1044-1051
• /
• 2016

The present study compared the differential functions of two groups of adjuvants, Montanide incomplete Seppic adjuvant (ISA) series and Quil A, cholesterol, dimethyl dioctadecyl ammonium bromide, and Carbopol (QCDC) formulations, in chicken by analyzing published microarray data associated with each type of vaccine adjuvants. In the biological function analysis for differentially expressed genes altered by two different adjuvant groups, ISA series and QCDC formulations showed differential effects when chickens were immunized with a recombinant immunogenic protein of Eimeria. Among the biological functions, six categories were modified in both adjuvant types. However, with respect to "Response to stimulus", no biological process was modified by the two adjuvant groups at the same time. The QCDC adjuvants showed effects on the biological processes (BPs) including the innate immune response and the immune response to the external stimulus such as toxin and bacterium, while the ISA adjuvants modified the BPs to regulate cell movement and the response to stress. In pathway analysis, ISA adjuvants altered the genes involved in the functions related with cell junctions and the elimination of exogenous and endogenous macromolecules. The analysis in the present study could contribute to the development of precise adjuvants based on molecular signatures related with their immunological functions.

• Journal of Applied Biological Chemistry
• /
• 제56권2호
• /
• pp.69-78
• /
• 2013

본 연구는 국내외에서 친환경유기농자재로 허용하고 있는 보조제 및 추출제 종류 및 세부사용조건을 분석 및 평가하여 허용조건을 제안하였다. Potassium hydroxide와 발효 ethyl alcohol은 국제적으로 친환경유기농자재의 추출제로서 허용되고 있고, 미국 환경청 (US EPA)에서 규정하고 있는 inert ingredient list 4에 해당하는 물질은 작물생산 보조제로서 사용되고 있다.

• 농약과학회지
• /
• 제8권4호
• /
• pp.325-331
• /
• 2004

본 연구는 서로 다른 보조제를 이용하여 살충제인 acetamipid 4% 액제(SL)의 제조처방을 확립하고 생물활성 검정을 통하여 보조제에 의한 살충활성의 증가효과를 검토하고자 수행되었다. 시험에 사용된 보조제는 SS(Sodium alkylcarboxylate)와 PE(Polyoxyethylene alkyl ether) 두가지 였으며, 기초적인 제제시험을 통하여 안정적인 액제 제조처방을 확립하고 선발된 보조제를 이용하여 각기 다른 4가지 제조처방을 가진 시제품을 제조하여 시험에 사용하였다. 각각의 시제품은 보조제 특성을 평가하기 위하여 기본적인 물리성을 측정하였고 오이를 대상으로 오이총채벌레(Thrips palmi) 및 목화진딧물(Aphis gossypii)에 대한 살충 활성을 비교하였다. 보조제가 첨가되지 않은 SL1의 경우, 보조제를 첨가하면서 표면장력이 44 dyne/cm에서 34 dyne/cm으로 감소하였고 접촉각은 SS와 PE의 혼합 보조제를 사용한 SL4에서 가장 낮은 값을 나타내었다. 오이 총채벌레 및 목화진딧물에 대한 살충활성은 보조제를 첨가함에 따라 증가하였고 단독 보조제를 사용한 SL2와 SL3보다는 SS와 PE의 혼합 보조제를 사용한 SL4에서 가장 우수한 활성을 나타내었다. 이상의 결과는 적절한 보조제의 선발에 의하여 살충제의 활성을 증가시킬 수 있고 이를 통하여 살충제의 처리량을 줄일 가능성이 있음을 보여주고 있다.

• BMB Reports
• /
• 제30권5호
• /
• pp.352-355
• /
• 1997

The surface adsorbed protein conformations onto the vaccine adjuvants were observed with a Raman spectroscopy by using the maximum adsorption conditions described previously. The adsorbed state Raman vibrational spectra and subsequent spectral analysis display no conformational changes for BSA or IgG relative to their native species in solution.

• 농약과학회지
• /
• 제12권4호
• /
• pp.421-428
• /
• 2008

Adjuvant 첨가에 의한 농약살포액의 이화학적 특성 및 약효증진 효과를 구명하기 위하여 시험한 결과, 농약살포액의 분무입경은 adjuvant의 첨가로 다소 작아지는 경향을 보였으며, 그 효과는 약제 및 보조제의 종류에 따라 상이하였다. 또한 보조제 첨가에 의한 농약의 작물체 부착량은 일정한 경향없이 살포 방법 및 살포량에 따라 상반된 효과를 나타냈다. Adjuvant에 의한 tricyclazole WP와 fenobucarb EC 희석액의 살포 6시간 후 강우처리시 내강우성은 벼의 부위에 따라 $1.5{\sim}4.1$배의 높은 증진효과를 보였다. 또한 보조제 첨가에 의한 Propanil EC의 피 방제효과는 무첨가에 비해 $8{\sim}30%$의 약효 증진 효과를 보여 적절한 보조제를 혼용함으로써 농약의 살포회수 및 사용량을 줄일 수 있는 가능성을 보였다.

• 한국어병학회지
• /
• 제22권1호
• /
• pp.45-52
• /
• 2009

Zebrafish was firstly applied to an experimental model for scuticociliatosis caused by Philasterides dicentrarchi, a facultative parasitic ciliate in cultured marine fish. The susceptibility of zebrafish to infection of P. dicentrarchi was assessed by intraperitoneal injection of the ciliates, which produced typical symptoms of scuticociliatosis and significant mortality. The potential use of zebrafish as a model to evaluate the vaccine efficacy against scuticociliatosis was analyzed by immunization of zebrafish with the ciliates lysate. Furthermore, the effect of different adjuvants, such as Quillaja saponin (QS), Montanide, and Freund’s incomplete adjuvant (FIA) on the protective efficacy of the vaccine was investigated. Groups of zebrafish injected with QS or Montanide alone showed higher survival of fish against challenge test compared to control fish. The results suggest that adjuvant-mediated enhancement of innate immune responses play important roles in protection of fish against scuticociliatosis. The considerably high survival in the fish immunized with the antigen alone indicates that the ciliate lysate itself is highly immunogenic to zebrafish, which can elicit protective immune responses. The protective potential of the antigen, ciliate lysate, was enforced through combined administration with adjuvants including QS, Montinide and FIA. No or low mortalities in the groups of fish immunized with the antigen plus adjuvants suggests that the adaptive immune responses of zebrafish might be accelerated by the adjuvants or the protective potential of the antigen and adjuvants might synergistically interact. In spite of several shortcomings such as difficulties in sampling of serum and leucocytes enough to routine immunological analyses, zebrafsih might be the most convenient experimental animal for scuticociliatosis.

• Journal of Yeungnam Medical Science
• /
• 제34권2호
• /
• pp.161-168
• /
• 2017

Peripheral nerve blocks are commonly used for surgical anesthesia, postoperative analgesia, and to reduce opioid requirements. Although these blocks have traditionally been carried out using local anesthetics, single-injection techniques can be short-lived and limited by the relatively brief duration of action of currently available local anesthetics. Increasing the dose or concentration of local anesthetics may prolong the duration of analgesia, but may also increase the risk such as unwanted motor weakness or systemic toxicity of local anesthetics. Numerous adjuvant medications have been added to local anesthetics to prolong the durations of anesthesia and analgesia achieved by peripheral nerve blocks, and currently, a number of different adjuvants are used to improve quality of the block. This article will review the several nerve block adjuvants used in combination with local anesthetics to provide blockade of peripheral nerves in clinical practice, describing the rationale for their use in peripheral nerve blocks, and the evidence for their effectiveness.